Affordable Access

deepdyve-link
Publisher Website

Passive Immunization With a Novel Monoclonal Anti-PrP Antibody TW1 in an Alzheimer’s Mouse Model With Tau Pathology

Authors
  • Boutajangout, Allal1, 2, 3, 4
  • Zhang, Wei5
  • Kim, Justin1, 2
  • Abdali, Wed Ali1, 2
  • Prelli, Frances1, 2
  • Wisniewski, Thomas1, 2, 3, 6
  • 1 Center for Cognitive Neurology, New York University Langone Health, New York, NY , (United States)
  • 2 Department of Neurology, New York University Langone Health, New York, NY , (United States)
  • 3 Department of Pathology, New York University Langone Health, New York, NY , (United States)
  • 4 Department of Physiology and Neuroscience, New York University Langone Health, New York, NY , (United States)
  • 5 Key Laboratory of Brain Functional Genomics (Ministry of Education) Shanghai, School of Life Sciences, East China Normal University, Shanghai , (China)
  • 6 Department of Psychiatry, New York University Langone Health, New York, NY , (United States)
Type
Published Article
Journal
Frontiers in Aging Neuroscience
Publisher
Frontiers Media SA
Publication Date
Feb 25, 2021
Volume
13
Identifiers
DOI: 10.3389/fnagi.2021.640677
PMCID: PMC7947695
Source
PubMed Central
Keywords
License
Unknown

Abstract

Neurofibrillary tangles (NFTs) are a major pathologic hallmark of Alzheimer’s disease (AD). Several studies have shown that amyloid β oligomers (Aβo) and tau oligomers mediate their toxicity, in part, via binding to cellular prion protein (PrPC) and that some anti-PrP antibodies can block this interaction. We have generated a novel monoclonal anti-PrP antibody (TW1) and assessed the efficacy of passive immunization with it in a mouse model of AD with extensive tau pathology: hTau/PS1 transgenic (Tg) mice. These mice were injected intraperitoneally once a week with TW1 starting at 5 months of age. Behavior was assessed at 8 months of age and brain tissue was subsequently harvested for analysis of treatment efficacy at 9 months. Mice treated with TW1 did not show any significant difference in sensorimotor testing including traverse beam, rotarod, and locomotor activity compared to controls. Significant cognitive benefits were observed with the novel object recognition test (ORT) in the immunized mice (two-tailed, t -test p = 0.0019). Immunized mice also showed cognitive benefits on the closed field symmetrical maze (day 1 two-tailed t -test p = 0.0001; day 2 two-tailed t -test p = 0.0015; day 3 two-tailed t -test p = 0.0002). Reduction of tau pathology was observed with PHF-1 immunohistochemistry in the piriform cortex by 60% (two-tailed t -test p = 0.01) and in the dentate gyrus by 50% (two-tailed t -test p = 0.02) in animals treated with TW1 compared to controls. There were no significant differences in astrogliosis or microgliosis observed between treated and control mice. As assessed by Western blots using PHF-1, the TW1 therapy reduced phosphorylated tau pathology (two-tailed t -test p = 0.03) and improved the ratio of pathological soluble tau to tubulin (PHF1/tubulin; two-tailed t -test p = 0.0006). Reduction of tau pathology also was observed using the CP13 antibody (two-tailed t -test p = 0.0007). These results indicate that passive immunization with the TW1 antibody can significantly decrease tau pathology as assessed by immunohistochemical and biochemical methods, resulting in improved cognitive function in a tau transgenic mouse model of AD.

Report this publication

Statistics

Seen <100 times